Want to see GDTC full AI Analyst Report?
GDTC Stock Chart & Stats
$0.95
-$0.41(-13.85%)
At close: 4:00 PM EST
$0.95
-$0.41(-13.85%)
Day’s Range― - ―
52-Week Range$0.68 - $3.68
Previous CloseN/A
Volume107.31K
Average Volume (3M)166.79K
Market Cap
$10.89M
Enterprise Value$14.85M
Total Cash (Recent Filing)$2.10M
Total Debt (Recent Filing)$482.56K
Price to Earnings (P/E)―
Beta0.05
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,832,835
10 Day Avg. Volume104,297
30 Day Avg. Volume166,789
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)3.07
Price to Sales (P/S)62.86
P/FCF Ratio-4.56
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue23.10
Enterprise Value/Gross Profit-112.78
Enterprise Value/Ebitda-2.82
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetLower leverage and a stronger equity base improve financial resilience and may extend operating runway. This provides more flexibility as CytoMed develops its pipeline, although ongoing losses mean the balance sheet is not yet producing shareholder returns.
R&D Capital CommitmentDedicated funding for an R&D laboratory can strengthen internal development capabilities, support product innovation and improve processes. If executed effectively, this may build longer-term differentiation in cord blood-derived therapeutics.
Strategic Manufacturing CapabilityAn existing cGMP facility combined with expanded research infrastructure can support more controlled development and manufacturing of therapeutics. This may improve execution capacity and help the company advance products toward commercialization over time.
Bears Say
Persistent UnprofitabilityPersistent operating and net losses indicate that the current business model has not yet achieved commercial scale or sustainable economics. Continued deficits can consume capital, increase financing dependence and constrain investment in the pipeline.
Ongoing Cash BurnSustained negative operating and free cash flow means operations are not self-funding. Intensifying cash burn raises the likelihood of additional external financing, which could increase dilution or create execution risk if funding becomes less available.
Weak Revenue EconomicsA small, volatile revenue base provides limited operating leverage and makes fixed development costs harder to absorb. The 2025 gross-profit loss suggests worsening unit economics or cost pressure, weakening confidence in near-term scalability.
CytoMed Therapeutics Limited News
GDTC FAQ
What was CytoMed Therapeutics Limited’s price range in the past 12 months?
CytoMed Therapeutics Limited lowest stock price was $0.68 and its highest was $3.68 in the past 12 months.
What is CytoMed Therapeutics Limited’s market cap?
CytoMed Therapeutics Limited’s market cap is $10.89M.
When is CytoMed Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CytoMed Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is CytoMed Therapeutics Limited overvalued?
According to Wall Street analysts CytoMed Therapeutics Limited’s price is currently Overvalued.
Does CytoMed Therapeutics Limited pay dividends?
CytoMed Therapeutics Limited does not currently pay dividends.
What is CytoMed Therapeutics Limited’s EPS estimate?
CytoMed Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoMed Therapeutics Limited have?
CytoMed Therapeutics Limited has 11,832,835 shares outstanding.
What happened to CytoMed Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CytoMed Therapeutics Limited?
Currently, no hedge funds are holding shares in GDTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Technical Analysis
Ownership Overview
34.84% Insiders
0.04% Mutual Funds
0.19% Other Institutional Investors
64.93% Public Companies and
Individual Investors